#AMRN

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology Amarin (NASDAQ: AMRN) highlighted a post hoc REDUCE-IT analysis published March 2026 in the European Journal of Preventive Cardiology showing icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost to hospitalization and death among 8,179 statin-treated participants followed for a median of five years.The paper underscores patient-centered benefits of IPE (VASCEPA/VAZKEPA) and notes prior REDUCE-IT results influenced guideline inclusion.

1 week ago

#AMRN Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

www.stocktitan.net/news/AMRN/effects-of-ico...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 weeks ago

#AMRN #73a4be20-9ec6-49ab-9481-5bfc43010b8c #earningscall-transcripts

Origin | Interest | Match

0 0 0 0

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit Amarin (NASDAQ:AMRN) praised the FDA for updating fenofibrate labeling on Oct 27, 2025, to state a lack of cardiovascular benefit and to add safety language and a narrowed indication.The label cites two large diabetes trials and PROMINENT, and warns of increased rhabdomyolysis risk when fibrates are combined with statins. The release notes >11 million US fibrate prescriptions in 2023, >60% co-prescribed with statins, and ~2 million fibrate patients in Western Europe.Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).

4 months ago

#AMRN Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

www.stocktitan.net/news/AMRN/amarin-issues-...

0 0 0 0

Breakthrough: EPA Drug Shows Dual Anti-Inflammatory Action in Heart Disease, Amarin Study Reveals at ESC New in vitro data shows EPA reduces inflammation in ASCVD via NLRP3 inflammasome modulation and inhibits Lp(a) oxidation. Research presented at ESC 2025 advances understanding of VASCEPA's mechanism.

6 months ago

#AMRN Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

www.stocktitan.net/news/AMRN/amarin-highlig...

0 0 0 0

Major Cardiovascular Risk Reduction Findings: Amarin's REDUCE-IT Trial Shows New Benefits Across Patient Types New analyses from REDUCE-IT trial reveal IPE's impact on CV risk in CKM syndrome, hospitalization rates, and mechanisms of action. Data to be presented at ESC Congress 2025 in Madrid.

6 months ago

#AMRN New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

www.stocktitan.net/news/AMRN/new-analyses-f...

0 0 0 0

Amarin Reports Second Quarter 2025 Financial Results Amarin Corporation (NASDAQ:AMRN) reported Q2 2025 financial results, highlighting two major strategic initiatives: a partnership with Recordati for European VAZKEPA® commercialization and a global restructuring targeting $70 million in cost savings over 12 months.Q2 2025 financial highlights include total net revenue of $72.7 million (up 8% YoY), with product revenue declining 2% to $46.6 million and licensing revenue increasing 31% to $26.1 million. The company reported a net loss of $14.1 million versus net income of $1.5 million in Q2 2024. Amarin maintains a strong balance sheet with $298.7 million in cash and no debt.The Recordati partnership covers VAZKEPA commercialization across 59 European countries, with transition expected to complete by end of 2025. The restructuring primarily involves eliminating European commercial roles.

7 months ago

#AMRN Amarin Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/AMRN/amarin-reports...

0 0 0 0

Amarin Strikes Massive European Deal: $175M Partnership Plus $70M Cost Savings Reshape Company Future Exclusive partnership with Recordati for VAZKEPA in 59 European countries brings $25M upfront, plus $150M potential milestones. See restructuring impact.

8 months ago

#AMRN Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

www.stocktitan.net/news/AMRN/amarin-announc...

0 0 0 0

Amarin Reports First Quarter 2025 Financial Results Amarin (AMRN) reported Q1 2025 financial results showing total net revenue of $42.0 million, down 26% from $56.5 million in Q1 2024. The company's U.S. revenue was $35.7 million, while European revenue reached $5.4 million. Operating expenses decreased 8% to $41.9 million. The company reported a net loss of $15.7 million or $0.04 per share. Notably, Amarin regained Nasdaq compliance following a 1-for-20 ADS ratio change effective April 11, 2025. European operations showed promise with 16% sequential quarter-over-quarter growth in market demand. The company maintains a strong balance sheet with $281.8 million in cash. In Italy, VAZKEPA now has patient access in 14 of 21 regions, covering 85% of the eligible population, while Austria secured national reimbursement starting April 1, 2025.

10 months ago

#AMRN Amarin Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/AMRN/amarin-reports...

0 0 0 0

11 months ago

News; ( NASDAQ: #AMRN ) AMRN announced stock split 1-20

0 0 0 0

Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug Latest research reveals EPA's effectiveness against Lp(a) oxidation and enhanced benefits when combined with GLP-1 drugs. Full cardiovascular impact analysis inside.

11 months ago

#AMRN Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

www.stocktitan.net/news/AMRN/amarin-highlig...

0 0 0 0

Trump

@trump.activitypub.awakari.com.ap.brid.gy

11 months ago

Original post on seekingalpha.com

Trump’s medical tariffs could significantly hurt these European healthcare firms

seekingalpha.com/news/4426700-trumps-medi...

#mdt #nvs #prgo #bayry #rhhby #fms #jazz #ste #amrn […]

1 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #AMRN ) Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #AMRN ) Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #AMRN ) Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

0 0 0 0

Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors Amarin implements strategic 1:20 ADR ratio adjustment targeting Nasdaq compliance. Key changes affect ADS holders while ordinary shares remain unchanged. New structure effective April 2025.

1 year ago

#AMRN Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

www.stocktitan.net/news/AMRN/amarin-announc...

0 0 0 0